Skip to content
Study details
Enrolling now

Edetate Calcium Disodium or Succimer for Leukemia Treatment

M.D. Anderson Cancer Center
NCT IDNCT03630991ClinicalTrials.gov data as of Apr 2026
Phase

Phase 1

Target enrollment

58

Study length

about 8.6 years

Ages

1+

Locations

1 site in TX

What this study is about

This trial is testing edetate calcium disodium or succimer in patients with acute myeloid leukemia or myelodysplastic syndrome undergoing chemotherapy. The goal is to determine the best dose and side effects of these treatments, which may help lower metals in the body and improve response to chemotherapy.

Simplified from trial records by PatientMatch.

What you may be asked to do

  • 1.Multivitamin
  • 2.Take Edetate Calcium Disodium
  • 3.Take Succimer

Participation Burden

What's physically and logistically required of participants.

Logistics & Travel
In-person visits

Requires travel to a study site

Physical Intervention
Oral

How treatment is administered

Treatment Assignment
All receive treatment

Everyone gets the investigational treatment.

Extracted study details

Pulled from the trial record to show what is being tested and what the study is measuring.

Drug classes

Antidotes, Deterrents, and Toxicologic Agents (Chelating Activity), Antidotes, Deterrents, and Toxicologic Agents (Lead Chelating Activity)

Drug routes

oral (Oral Capsule)

Endpoints

Primary: Incidence of adverse events, Maximum tolerated doses (MTD) of edetate calcium disodium (Ca-EDTA) and succimer (DMSA) (Phase 1 dose escalation)

Body systems

Oncology